Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943309 | 0.89 | CNR1 (0.80) | CNR1NPC1RAB9A | |
| SCHEMBL5943307 | 0.89 | CNR1 (0.80) | CNR1NPC1RAB9A | |
| SCHEMBL4455038 | 0.88 | CNR1 (1.00) | CNR1NPC1RAB9A | |
| SCHEMBL4456100 | 0.88 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4452937 | 0.87 | CNR1 (0.77) | CNR1NPC1RAB9A | |
| SCHEMBL5769982 | 0.86 | CNR1 (1.00) | CNR1 | |
| Hydrochloric Acid SCHEMBL5771259 | 0.85 | CNR1 (0.74) | CNR1 | |
| SCHEMBL4245822 | 0.85 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4457176 | 0.84 | CNR1 (1.00) | CNR1NPC1RAB9A | |
| SCHEMBL5768876 | 0.84 | CNR1 (0.79) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473693-B2 | Stable dispersion of solid particles comprising a water-insoluble pyrazine compound | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | claimed |
| EP-1592451-B1 | STABLE DISPERSION OF SOLID PARTICLES COMPRISING A WATER-INSOLUBLE PYRAZINE COMPOUND | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | claimed |
| US-7342019-B2 | 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | claimed |
| EP-1458690-B1 | 5,6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | EP | claimed |
| US-20060134146-A1 | Stable dispersion of solid particles comprising a water-insoluble pyrazine compound | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | claimed |
| EP-1592451-A1 | STABLE DISPERSION OF SOLID PARTICLES COMPRISING A WATER-INSOLUBLE PYRAZINE COMPOUND | AstraZeneca AB (SE) | 2005-11-09 | — | — | EP | claimed |
| US-20050032808-A1 | 5 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists | ASTRAZENECA AB (SE) | 2005-02-10 | — | — | US | claimed |
| EP-1458690-A1 | 5,6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS | Astrazeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2004069277-A1 | STABLE DISPERSION OF SOLID PARTICLES COMPRISING A WATER-INSOLUBLE PYRAZINE COMPOUND | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2003051850-A1 | PYRAZINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| WO-2003051851-A1 | 5, 6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| US-7473693-B2 | Stable dispersion of solid particles comprising a water-insoluble pyrazine compound | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| EP-1592451-B1 | STABLE DISPERSION OF SOLID PARTICLES COMPRISING A WATER-INSOLUBLE PYRAZINE COMPOUND | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-7342019-B2 | 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1458690-B1 | 5,6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| US-20050032808-A1 | 5 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists | ASTRAZENECA AB (SE) | 2005-02-10 | — | — | US | disclosed |
| EP-1458690-A1 | 5,6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS | Astrazeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004069277-A1 | STABLE DISPERSION OF SOLID PARTICLES COMPRISING A WATER-INSOLUBLE PYRAZINE COMPOUND | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2003051850-A1 | PYRAZINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051851-A1 | 5, 6-DIARYL-PYRAZINE-2-AMIDE DERIVATIVES AS CB1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134146-A1 | Stable dispersion of solid particles comprising a water-insoluble pyrazine compound | SKP1, SPOP, ABCG2 | CNR1 4128/4885NPC1 1728/4885RAB9A 3312/4885 |
| US-20050032808-A1 | 5 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists | CNR1, CNR2, GPR18 | CNR1 1/4885NPC1 878/4885RAB9A 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.